Due to a more favourable environment, EDITAS MEDICINE slightly increases to Slightly Negative
EDITAS MEDICINE (US), a company active in the Biotechnology industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as risky. At the fundamental level, theScreener confirms the rating of 1 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Slightly Negative even if it remains under pressure. As of the analysis date February 11, 2022, the closing price was USD 16.13 and its target price was estimated at USD 14.08.Editas Medicine is a clinical stage genome editing company focused on developing genomic medicines to treat a range of serious diseases. The company has developed a proprietary genome editing platform based on clustered, regularly interspaced, short palindromic repeats (CRISPR) technology. The company is developing both in vivo CRISPR medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and engineered cell medicines, in which cells are edited with the company's technology and then administered to the patient. In ocular diseases, the company's program is designed to address a specific genetic form of retinal degeneration called Leber congenital amaurosis 10.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.